Get the Stockscreener App
86.28
1.37%
1.17
Pre-market:
88.50
2.22
+2.57%
Edwards Lifesciences Corp stock is traded at $86.28, with a volume of 2.93M.
It is up +1.37% in the last 24 hours and up +6.02% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$85.11
Open:
$85.3
24h Volume:
2.93M
Relative Volume:
0.58
Market Cap:
$49.68B
Revenue:
$6.30B
Net Income/Loss:
$1.07B
P/E Ratio:
46.88
EPS:
1.8406
Net Cash Flow:
$1.09B
1W Performance:
+0.50%
1M Performance:
+6.02%
6M Performance:
+3.48%
1Y Performance:
+14.81%
1-Day Range:
$84.61
$86.31
1-Week Range:
$83.17
$87.93
52-Week Range:
$72.30
$89.48
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
86.28 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
88.67 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Edwards Lifesciences Corp. stock rises Monday, still underperforms market - MarketWatch
Edwards Lifesciences Stock (US28176E1082): Valuation Metrics Under the Microscope - AD HOC NEWS
Is Edwards Lifesciences stock underperforming the Nasdaq? - MSN
Sector Gamma AS Acquires 23,422 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Parnassus Investments LLC Acquires 111,843 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Stock Watched As Procedure Recovery Matters - Kalkine Media
Deutsche Bank AG Has $475.59 Million Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
CIBC Asset Management Inc Grows Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
Edwards Lifesciences (NYSE:EW) Hits New 1-Year HighTime to Buy? - MarketBeat
Edwards Tricuspid Valve Gets FDA OK - Orange County Business Journal
Possible Bearish Signals With Edwards Lifesciences Insiders Disposing Stock - Yahoo Finance
Edwards Lifesciences Corp. Hits New 52-Week High at $89.14 - MarketsMojo
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Edwards Holds Annual Patient Experience Day - Orange County Business Journal
Is Edwards Lifesciences Stock Underperforming the Nasdaq? - Barchart.com
TD Cowen Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $104 - Moomoo
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Bank of New York Mellon Corp Sells 1,517,638 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
TD Cowen raises Edwards Lifesciences stock price target on TAVR market share gains - Investing.com
Nomura Asset Management Co. Ltd. Has $36.83 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
EW Technical Analysis | Trend, Signals & Chart Patterns | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences (EW) CFO Theodora Mistras files initial Form 3 report - Stock Titan
Intech Investment Management LLC Has $5.91 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Insider Sell: Andrew Dahl Sells Shares of Edwards Lifesciences C - GuruFocus
Geode Capital Management LLC Trims Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Andrew Dahl Sells 568 Shares of Edwards Lifesciences (NYSE:EW) Stock - MarketBeat
Edwards Lifesciences (EW) SVP records small open-market stock sale - Stock Titan
Edwards Lifesciences (NYSE: EW) affiliate reports two 13,000-share sales - Stock Titan
Edwards Lifesciences (NYSE: EW) files Form 144 for proposed common sale - Stock Titan
Boston Scientific’s $1.5B bet signals heart valve market battle - Modern Healthcare
Edwards Lifesciences Corp. Hits New 52-Week High at USD 88.25 - Markets Mojo
Edwards Lifesciences Corp. Hits New 52-Week High at USD 87.93 - Markets Mojo
Allstate Corp Grows Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Is Edwards Lifesciences (EW) Fairly Priced After Recent Share Price Strength? - Yahoo Finance
Edwards Lifesciences CVP Donald Bobo Jr. sells $2m in stock - Investing.com UK
Edwards Lifesciences CVP Donald Bobo Jr. sells $2m in stock By Investing.com - Investing.com Australia
Edwards Lifesciences (EW) executive sells 23,145 shares at $86.42 average price - Stock Titan
Donald Bobo reports multiple Common stock sales (EW) in Form 144 - Stock Titan
Edwards Lifesciences Has Everything Investors Want Except Value (NYSE:EW) - Seeking Alpha
Legal & General Group Plc Has $376.46 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences stock hits 52-week high at 87.89 USD - Investing.com
Edwards Lifesciences stock hits 52-week high at 87.89 USD By Investing.com - Investing.com UK
EWEdwards Lifesciences Corp Stock Price and Quote - Finviz
Swedbank AB Lowers Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences’ SWOT analysis: stock gains from rival’s setback By Investing.com - Investing.com Australia
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.32%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):